Sulphonyl Urea Derivatives for Selective NLRP3 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for NLRP3-dependent inflammatory disorders lack compounds with improved physicochemical, pharmacological, and pharmaceutical properties, and existing NLRP3 modulators face limitations in therapeutic utility due to non-specificity and potential side effects.
Innovation Solution
Development of sulphonyl urea derivatives and their pharmaceutically acceptable salts, which act as selective inhibitors of the NLRP3 inflammasome, offering improved physicochemical and pharmacological properties for targeted modulation of NLRP3-dependent cellular processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing NLRP3 modulators are used, then inflammasome activity is inhibited, but the compounds lack specificity and cause potential side effects
Solution Approach 1:
The patent applies local quality by designing sulphonyl urea derivatives with specific structural features (R1-R6 substituents) that enable selective binding to NLRP3 inflammasome components. The compounds exhibit preferential activity against NLRP3 over other inflammasome members, achieving localized molecular recognition and action that reduces off-target effects and improves therapeutic specificity.
2Reliability
If existing NLRP3 modulators are used, then inflammasome activity is inhibited, but the compounds have limited therapeutic utility
Solution Approach 1:
The patent demonstrates universality by developing a series of sulphonyl urea derivatives that can be applied across multiple disease indications. The compounds inhibit NLRP3-dependent processes in diverse conditions including gout, atherosclerosis, Alzheimer's disease, Parkinson's disease, and various autoimmune disorders, enabling a single molecular framework to address multiple therapeutic areas through structure-activity relationship optimization.
3Reliability
If existing NLRP3 modulators are used, then inflammasome activity is inhibited, but the compounds have suboptimal physicochemical properties
Solution Approach 1:
The patent applies parameter changes by systematically varying structural parameters (R1-R6 substituents) of the sulphonyl urea core to optimize physicochemical properties. Modifications include adjusting molecular weight, lipophilicity, and functional group composition to achieve optimal absorption, distribution, metabolism, and excretion characteristics, thereby improving oral bioavailability and pharmacological performance.
Data Source
AI summary
The present disclosure relates to compounds of Formula (I):and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.